Claims
- 1. An amide of the following formula I,
- wherein:
- E is selected from nitrogen and CZ wherein C is a ring carbon and Z is a substituent defined below, wherein:
- X is ArY wherein Y is a linking group, carbonyl, and Ar is selected from the group consisting of:
- six-membered heteroaryl rings containing 1-2 nitrogen atoms as the only heteroatoms; and
- five-membered heteroaryl rings containing from 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; provided that Ar is not 4-pyridyl or 5-pyrimidinyl;
- z is selected from hydrogen, cyano, halo, hydroxy, (1-4C)alkyl, and (1-4C)alkoxy; and
- R.sup.2 and R.sup.3
- are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 groups selected from fluoro and chloro wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl; or
- together, with the carbon atom to which both R.sup.2 and R.sup.3 are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 0 to 2m-2 fluoro groups wherein m is the number of carbon atoms in said ring;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide; or a pharmaceutically acceptable salt of said amide or said ester.
- 2. An amide as claimed in claim 1 which is of the following formula Id, ##STR3## wherein: X is ArY wherein
- Y is a linking group, carbonyl, and Ar is selected from the group consisting of 2-, and 3-pyridyl, 2- and 4-pyrimidinyl, 3- and 4-isothiazolyl, 2- and 4-oxazolyl, 2- and 4-thiazolyl, 2- and 3-furyl, and 2- and 3-thienyl;
- z is selected from hydrogen, cyano, halo, hydroxy, (1-2C)alkyl, and (1-2C)alkoxy; and
- R.sup.2 and R.sup.3 are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 fluoro groups wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide;
- or a pharmaceutically acceptable salt of said amide or said ester.
- 3. An amide as claimed in claim 2, wherein Z is hydrogen, Ar is 2-pyridyl; and
- R2 and R3 are independently selected from the group consisting of
- (i) R.sup.2 is trifluoromethyl and R.sup.3 is selected from methyl, ethyl, and trifluoromethyl; and
- (ii) R.sup.2 is difluoromethyl and R.sup.3 is difluoromethyl;
- or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide; or a pharmaceutically acceptable salt of said amide or said ester.
- 4. A pharmaceutical composition comprising an amide of the following formula I, or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide, or a pharmaceutically acceptable salt of said amide or of said ester, ##STR4## wherein: E is selected from nitrogen and CZ wherein C is a ring carbon and Z is a substituent defined below, wherein:
- X is ArY wherein Y is a linking group, carbonyl, and Ar is selected from the group consisting of:
- six-membered heteroaryl rings containing 1-2 nitrogen atoms as the only heteroatoms; and
- five-membered heteroaryl rings containing from 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; provided that Ar is not 4-pyridyl, or 5-pyrimidinyl;
- Z is selected from hydrogen, cyano, halo, hydroxy, (1-4C)alkyl, and (1-4C)alkoxy; and
- R.sup.2 and R.sup.3
- are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 groups selected from fluoro and chloro wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl; or
- together, with the carbon atom to which both R.sup.2 and R.sup.3 are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 0 to 2m-2 fluoro groups wherein m is the number of carbon atoms in said ring;
- and a pharmaceutically acceptable diluent or carrier.
- 5. A composition as claimed in claim 4 wherein said amide is of the following formula Id, ##STR5## and wherein: X is ArY wherein
- Y is a linking group, carbonyl, and Ar is selected from the group consisting of 2-, and 3-pyridyl, 2- and 4-pyrimidinyl, 3- and 4-isothiazolyl, 2- and 4-oxazolyl, 2- and 4-thiazolyl, 2- and 3-furyl, and 2- and 3-thienyl;
- Z is selected from hydrogen, cyano, halo, hydroxy, (1-2C)alkyl, and (1-2C)alkoxy; and
- R.sup.2 and R.sup.3 are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 fluoro groups wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl.
- 6. A composition as claimed in claim 5, wherein
- Z is hydrogen, Ar is 2-pyridyl; and
- R2 and R3 are independently selected from the group consisting of
- (i) R.sup.2 is trifluoromethyl and R.sup.3 is selected from methyl, ethyl, and trifluoromethyl; and
- (ii) R.sup.2 is difluoromethyl and R.sup.3 is difluoromethyl;
- or a pharmaceutically acceptable in vivo hydrolyzable esters of said amide.
- 7. A method of treating urinary incontinence, comprising administering to a mammal in need of such treatment an effective amount of an amide of the following formula I, or a pharmaceutically acceptable in vivo hydrolyzable ester of said amide, or a pharmaceutically acceptable salt of said amide or of said ester, ##STR6## wherein: E is selected from nitrogen and CZ wherein C is a ring carbon and Z is a substituent defined below, wherein:
- X is ArY wherein Y is a linking group, carbonyl, and Ar is selected from the group consisting of:
- six-membered heteroaryl rings containing 1-2 nitrogen atoms as the only heteroatoms; and
- five-membered heteroaryl rings containing from 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; provided that Ar is not 4-pyridyl or 5-pyrimidinyl;
- Z is selected from hydrogen, cyano, halo, hydroxy, (1-4C)alkyl, and (1-4C)alkoxy; and
- R.sup.2 and R.sup.3
- are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 groups selected from fluoro and chloro wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl; or
- together, with the carbon atom to which both R.sup.2 and R.sup.3 are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 0 to 2m-2 fluoro groups wherein m is the number of carbon atoms in said ring.
- 8. A method as claimed in claim 7 wherein said amide is of the following formula Id, ##STR7## wherein: X is ArY wherein
- Y is a linking group, carbonyl, and Ar is selected from the group consisting of 2, and 3-pyridyl, 2- and 4-pyrimidinyl, 3- and 4-isothiazolyl, 2- and 4-oxazolyl, 2- and 4-thiazolyl, 2- and 3-furyl, and 2- and 3-thienyl;
- Z is selected from hydrogen, cyano, halo, hydroxy, (1-2C)alkyl, and (1-2C)alkoxy; and
- R.sup.2 and R.sup.3 are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 fluoro groups wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl.
- 9. A method as claimed in claim 8, wherein Z is hydrogen, Ar is 2-pyridyl; and
- R2 and R3 are independently selected from the group consisting of
- (i) R.sup.2 is trifluoromethyl and R.sup.3 is selected from methyl, ethyl, and trifluoromethyl; and
- (ii) R.sup.2 is difluoromethyl and R.sup.3 is difluoromethyl.
- 10. An amide of the following formula I, ##STR8## wherein: E is selected from nitrogen and CZ wherein C is a ring carbon and Z is a substituent defined below, wherein:
- X is ArY wherein Y is a linking group, carbonyl, and Ar is selected from the group consisting of:
- six-membered heteroaryl rings containing 1-2 nitrogen atoms as the only heteroatoms; and
- five-membered heteroaryl rings containing from 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; provided that Ar is not 4-pyridyl or 5-pyrimidinyl;
- Z is selected from hydrogen, cyano, halo, hydroxy, (1-4C)alkyl, and (1-4C)alkoxy; and
- R.sup.2 and R.sup.3
- are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 groups selected from fluoro and chloro wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl; or
- together, with the carbon atom to which both R.sup.2 and R.sup.3 are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 0 to 2m-2 fluoro groups wherein m is the number of carbon atoms in said ring.
- 11. An amide as claimed in claims 10 which is of the following formula Id, ##STR9## wherein: X is ArY wherein
- Y is a linking group, carbonyl and Ar is selected from the group consisting of 2, and 3-pyridyl, 2- and 4-pyrimidinyl, 3- and 4-isothiazolyl, 2- and 4-oxazolyl, 2- and 4-thiazolyl, 2- and 3-furyl, and 2- and 3-thienyl;
- Z is selected from hydrogen, cyano, halo, hydroxy, (1-2C)alkyl, and (1-2C)alkoxy; and
- R.sup.2 and R.sup.3 are independently selected from the group consisting of (1-3C)alkyl substituted by from 0 to 2k+1 fluoro groups wherein k is the number of carbon atoms in the said (1-3C)alkyl, provided that R.sup.2 and R.sup.3 are not both methyl.
- 12. An amide as claimed in claim 11, Z is hydrogen, Ar is 2-pyridyl; and
- R2 and R3 are independently selected from the group consisting of
- (i) R.sup.2 is trifluoromethyl and R.sup.3 is selected from methyl, ethyl, and trifluoromethyl; and
- (ii) R.sup.2 is difluoromethyl and R.sup.3 is difluoromethyl.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9116069.7 |
Jul 1991 |
GBX |
|
9209416.8 |
Apr 1992 |
GBX |
|
Parent Case Info
This is a division of application Ser. No. 08/126,350, filed Sep. 24, 1983now U.S. Pat No. 5,382,598, which was a division of Application Ser. No. 07/918,982 filed Jul. 23, 1992, now U.S. Pat. No. 5,272,163.
US Referenced Citations (14)
Foreign Referenced Citations (8)
Number |
Date |
Country |
0181568 |
May 1986 |
EPX |
0189142 |
Jul 1986 |
EPX |
0253503 |
Jan 1988 |
EPX |
0274867 |
Jul 1988 |
EPX |
0409413 |
Jan 1991 |
EPX |
0409414 |
Jan 1991 |
EPX |
7008627 |
Jun 1969 |
NLX |
7008629 |
Jun 1969 |
NLX |
Non-Patent Literature Citations (2)
Entry |
R. Bayles et al., "The Smiles rearrangement of 2-aryloxy-2-methylpropanamides. Synthesis of N-aryl-2-hydroxy-2-methylpropanamides" Synthesis. (1977), 31-33. |
G. Edwards et al., "Structure-activity relationships of potassium channel openers", Trends in Pharmacological Sciences. (1990), 11, 417-422. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
126350 |
Sep 1993 |
|
Parent |
918982 |
Jul 1992 |
|